Factorial study of moxibustion in treatment of diarrhea-predominant irritable bowel syndrome

doi:10.3748/wjg.v20.i37.13563

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 37

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11026)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

629

WORD

293

HTML

6521

Figures (1-2)

470

Tables (1-4)

464

Sum=8377

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1098

Download

1551

Sum=2649

Oct 7, 2014 (publication date) through Dec 2, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Clinical Trials Study

World J Gastroenterol. Oct 7, 2014; 20(37): 13563-13572
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13563

Table 1 An analysis of the general baseline conditions of the patients in each group

	Group 1	Group 2	Group 3	Group 4	P value
n	40	40	40	40
Age (yr)	55	46.5	51.5	52	0.196
Gender					0.330
Male	42.5%	45%	42.5%	45%
Female	57.5%	55%	57.5%	55%
Disease duration (yr)	3	5	4	5	0.300
Disease severity scores	231.7 ± 68.0	221.5 ± 79.2	233.3 ± 73.9	241.5 ± 79.3	0.698

Group 1: 1 cone of moxibustion per treatment, 3 treatments/wk; Group 2: 1 cone of moxibustion per treatment, 6 treatments/wk; Group 3: 2 cones of moxibustion per treatment, 3 treatments/wk; Group 4: 2 cones of moxibustion per treatment, 6 treatments/wk.

Full Size Table

Table 2 Comparisons of the symptom scores for patients in each group at different stages of treatment

Group	n		Birmingham	IBS-QOL	SDS	SAS	HAMD	HAMA
Group 1	40	Before	21.10 ± 8.62	75.75 ± 21.72	45.33 ± 11.04	42.83 ± 9.62	6.13 ± 5.43	5.90 ± 5.22
		1^st course	11.60 ± 7.53^a	60.20 ± 14.82^a	36.20 ± 8.37^a	36.65 ± 9.37^a	3.75 ± 3.40^a	4.05 ± 3.57^a
		2^nd course	5.55 ± 5.05^a^b^c	50.65 ± 10.86^a^b	32.43 ± 6.94^a^b	32.08 ± 6.95^a^b	1.75 ± 2.31^a^b	2.23 ± 2.90^a^b
Group 2	40	Before	23.45 ± 8.25	75.38 ± 21.02	43.45 ± 13.93	43.10 ± 12.86	7.25 ± 7.06	6.68 ± 4.74
		1^st course	15.58 ± 9.15^a	59.40 ± 18.02^a	38.13 ± 10.54^a	37.35 ± 10.03^a	4.03 ± 3.28^a	3.28 ± 3.03^a
		2^nd course	10.45 ± 6.61^a^b	47.90 ± 10.49^a^b	32.53 ± 7.26^a^b	32.25 ± 7.14^a^b	1.98 ± 2.38^a^b	1.93 ± 2.14^a^b
Group 3	40	Before	21.50 ± 8.82	78.53 ± 24.22	46.80 ± 13.53	46.15 ± 12.74	9.05 ± 6.54	7.53 ± 5.37
		1^st course	13.03 ± 8.23^a	58.28 ± 13.39^a	38.40 ± 10.41^a	37.95 ± 8.65^a	4.60 ± 2.77^a	3.98 ± 2.30^a
		2^nd course	5.65 ± 4.00^a^b^c	48.83 ± 9.38^a^b	32.50 ± 7.95^a^b	33.70 ± 7.00^a^b	2.10 ± 1.95^a^b	2.20 ± 1.60^a^b
Group 4	40	Before	23.65 ± 7.62	76.88 ± 19.90	46.00 ± 12.59	44.38 ± 12.02	7.50 ± 7.66	6.63 ± 4.78
		1^st course	13.95 ± 7.69^a	60.00 ± 16.09^a	38.15 ± 9.76^a	37.23 ± 10.50^a	4.10 ± 4.89^a	3.68 ± 2.67^a
		2^nd course	8.38 ± 6.17^a^b	48.48 ± 13.87^a^b	32.38 ± 9.15^a^b	33.45 ± 8.73^a^b	1.90 ± 3.04^a^b	2.20 ± 2.39^a^b

Group 1: One cone of moxibustion per treatment, three treatments/wk; Group 2: One cone of moxibustion per treatment, six treatments/wk; Group 3: Two cones of moxibustion per treatment, three treatments/wk; Group 4: Two cones of moxibustion per treatment, six treatments/wk; Before: Before treatment; 1^st course: After the first course of treatment; 2^nd course: After the second course of treatment; Birmingham: Birmingham irritable bowel syndrome symptom questionnaire; IBS-QOL: Irritable bowel syndrome Quality of Life Scale; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; HAMD: Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale. Compared with the first course after treatment;

^aP < 0.001 vs before treatment;

^bP < 0.001 vs the first course after treatment;

^cP < 0.001 vs group 2.

Full Size Table

Table 3 Comparisons of the degrees of improvement in symptoms and relevant scales for patients in each group at different stages of treatment

				Frequency		P value
	Scale	n	Cone	Three treatments/wk	Six treatments/wk	Cone	Frequency	Conefrequency
	Birmingham	40	1	42.24 ± 36.12	35.20 ± 23.84	0.643	0.845	0.254
	Birmingham	40	2	30.30 ± 77.95	40.25 ± 29.15	0.643	0.845	0.254
	IBS-QOL	40	1	17.40 ± 19.04	20.25 ± 14.37	0.255	0.847	0.348
	IBS-QOL	40	2	22.63 ± 15.67	20.76 ± 13.83	0.255	0.847	0.348
	SDS	40	1	17.99 ± 17.02	10.49 ± 9.66	0.734	0.133	0.140
1^st course	SDS	40	2	15.13 ± 19.32	15.06 ± 15.81	0.734	0.133	0.140
	SAS	40	1	13.72 ± 13.53	11.96 ± 9.97	0.279	0.535	0.849
	SAS	40	2	15.65 ± 13.50	14.72 ± 16.67	0.279	0.535	0.849
	HAMD	40	1	27.69 ± 48.61	39.54 ± 32.69	0.347	0.071	0.987
	HAMD	40	2	33.78 ± 40.44	45.84 ± 42.93	0.347	0.071	0.987
	HAMA	40	1	12.04 ± 65.36	46.90 ± 28.61	0.458	0.011	0.028
	HAMA	40	2	33.62 ± 44.65	36.19 ± 37.95	0.458	0.011	0.028
	Birmingham	40	1	73.74 ± 19.43	56.19 ± 21.62	0.393	0.002	0.078
	Birmingham	40	2	70.46 ± 27.24	65.56 ± 20.91	0.393	0.002	0.078
	IBS-QOL	40	1	29.98 ± 16.59	34.26 ± 13.63	0.247	0.208	0.562
	IBS-QOL	40	2	34.02 ± 15.29	35.60 ± 12.88	0.247	0.208	0.562
	SDS	40	1	26.12 ± 16.15	21.65 ± 14.35	0.149	0.373	0.373
2^nd course	SDS	40	2	27.51 ± 17.52	27.51 ± 15.12	0.149	0.373	0.373
	SAS	40	1	23.68 ± 12.83	22.54 ± 12.14	0.871	0.604	0.996
	SAS	40	2	24.02 ± 15.77	22.90 ± 13.81	0.871	0.604	0.996
	HAMD	40	1	63.06 ± 36.74	68.88 ± 32.05	0.139	0.182	0.845
	HAMD	40	2	69.63 ± 30.35	77.45 ± 29.05	0.139	0.182	0.845
	HAMA	40	1	49.62 ± 46.44	62.61 ± 38.66	0.502	0.238	0.450
	HAMA	40	2	59.19 ± 49.29	62.04 ± 32.62	0.502	0.238	0.450

1^st course: After the first course of treatment; 2^nd course: After the second course of treatment; Birmingham: Birmingham irritable bowel syndrome symptom questionnaire; IBS-QOL: Irritable bowel syndrome Quality of Life Scale; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; HAMD: Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale.

Full Size Table

Table 4 Correlation analysis of the degrees of improvements in relevant scales and the degrees of symptom improvement

Group	n	Degrees of symptom improvement(Birmingham)	Degrees of improvements inrelevant scales		r	P value
Aconite cake-separated moxibustion groups	160	66.49 ± 23.25	IBS-QOL	33.46 ± 14.68	0.080	0.317
			SDS	25.70 ± 15.87	0.165	0.037
			SAS	23.28 ± 13.59	0.161	0.042
			HAMD	69.75 ± 32.28	0.088	0.276
			HAMA	58.36 ± 42.19	0.331	0.077

Birmingham: Birmingham irritable bowel syndrome symptom questionnaire; IBS-QOL: Irritable bowel syndrome Quality of Life Scale; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; HAMD: Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale.

Full Size Table

Citation: Zhao JM, Wu LY, Liu HR, Hu HY, Wang JY, Huang RJ, Shi Y, Tao SP, Gao Q, Zhou CL, Qi L, Ma XP, Wu HG. Factorial study of moxibustion in treatment of diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 2014; 20(37): 13563-13572
URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13563.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13563

Zhao JM, Wu LY, Liu HR, Hu HY, Wang JY, Huang RJ, Shi Y, Tao SP, Gao Q, Zhou CL, Qi L, Ma XP, Wu HG. Factorial study of moxibustion in treatment of diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 2014; 20(37): 13563-13572 [PMID: 25309087 DOI: 10.3748/wjg.v20.i37.13563]

©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA